GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » PB Ratio

DexTech Medical AB (XSAT:DEX) PB Ratio : 2.45 (As of Jun. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-15), DexTech Medical AB's share price is kr4.10. DexTech Medical AB's Book Value per Share for the quarter that ended in Mar. 2024 was kr1.67. Hence, DexTech Medical AB's PB Ratio of today is 2.45.

The historical rank and industry rank for DexTech Medical AB's PB Ratio or its related term are showing as below:

XSAT:DEX' s PB Ratio Range Over the Past 10 Years
Min: 1.29   Med: 13.45   Max: 50.1
Current: 2.49

During the past 11 years, DexTech Medical AB's highest PB Ratio was 50.10. The lowest was 1.29. And the median was 13.45.

XSAT:DEX's PB Ratio is ranked worse than
50.46% of 1302 companies
in the Biotechnology industry
Industry Median: 2.465 vs XSAT:DEX: 2.49

During the past 12 months, DexTech Medical AB's average Book Value Per Share Growth Rate was -12.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 29.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 6.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -0.70% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of DexTech Medical AB was 34.10% per year. The lowest was -29.60% per year. And the median was -4.65% per year.

Back to Basics: PB Ratio


DexTech Medical AB PB Ratio Historical Data

The historical data trend for DexTech Medical AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB PB Ratio Chart

DexTech Medical AB Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.30 55.85 75.34 2.29 2.42

DexTech Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 2.42 2.40 2.25 3.56

Competitive Comparison of DexTech Medical AB's PB Ratio

For the Biotechnology subindustry, DexTech Medical AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's PB Ratio falls into.



DexTech Medical AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

DexTech Medical AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=4.10/1.672
=2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


DexTech Medical AB  (XSAT:DEX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


DexTech Medical AB PB Ratio Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB (XSAT:DEX) Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a strong clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.